BRAF and non-small cell lung carcinoma: A phase II clinical trial of 36 patients with NSCLC from 19 centers has shown that the presence of BRAFV600E mutation could be associated with increased responsiveness to combination therapy of dabrafenib and trametinib, which act as oral inhibitors of BRAF and MEK, respectively [75].